NeuroNOS

Proud to share: the FDA has granted Orphan Drug Designation to BA-101 for Glioblastoma (GBM) — the most common malignant brain cancer in adults. This is our 2nd ODD in 2025, advancing our mission to deliver targeted nitric-oxide–modulating therapies. stocks.apple.com/AiEjITBE8QwCR7…

(Nasdaq: $XAIR) @Neuro_NOS , a Beyond Air subsidiary, has been granted FDA Orphan Drug Designation for BA-101 in glioblastoma, one of the deadliest brain cancers. With few advances in treatment in decades, BA-101’s nitric oxide modulation approach could represent a breakthrough for patients. prismmarketview.com/neuronos-wins-…

Glioblastoma (GBM) is the most aggressive brain cancer, with survival often measured in months despite current treatments. At NeuroNOS, we’re developing a novel nNOS inhibitor to rebalance nitric oxide signaling that fuels tumor growth. #NeuroNOS #Glioblastoma #braincancercure

In a landmark Redox Biology review, our CSO Prof. @haitham_amal (@NeuroNOS) with Tripathi & Kartawy highlighted how NO dysregulation drives brain disorders. We’re building on these insights with a selective nNOS inhibitor for ASD. @Elsevier #NeuroNOS #AutismResearch #NitricOxide

We’re proud our CSO, Prof. @haitham_amal, will speak at #Synchrony2025 on Aug 22! His nitric oxide work shapes our mission at @Neuro_NOS. Thanks to the BRAIN foundation, @BostonChildrens, @HebrewU, and the Rosamund Stone Zander Center for advancing this dialogue #AutismResearch

#ThrowbackThursday: Prof. @haitham_amal’s lab (our CSO) found disrupted autophagy proteins in two ASD models, driven by NO imbalance. Blocking nNOS restored normal function—reinforcing NeuroNOS’s approach to rebalance NO & tackle core ASD biology. #AutismResearch #NeuroNOS

Nitric oxide (NO) is vital in balance, too much from nNOS fuels nitrosative stress, disrupting synapses. Research by our CSO, Prof. @haitham_amal, links this to ASD. At NeuroNOS, we’re developing a selective nNOS inhibitor to restore brain balance. #ASD #BrainHealth #NitricOxide

#ThrowbackThursday: A 2022 Free Radical Biology & Medicine paper by @haitham_amal revealed how nitric oxide disrupts NMDA receptor signaling in ASD models. At NeuroNOS, we’re targeting that biology with our selective nNOS inhibitor. #ASD #NitricOxide #TBT @ElsevierConnect

Lifetime autism care may exceed $4M per person (Zhao et al., 2024). Most treatments manage symptoms, few target root biology. At NeuroNOS, we’re developing a first-in-class drug to rebalance NO signaling in ASD. #NeuroNOS #Autism #ASD #NitricOxide #HealthEconomics

📽️Sneak peak: We spoke with three world-class scientists, joined by our two extraordinary Nobel Laureates who serve on our Scientific Advisory Board (SAB), as well as our CSO, to discuss our novel small-molecule nitric oxide inhibition platform for autism. #NobelPrize #Autism

Proud to share that our CSO, Prof. @haitham_amal Amal, joins the #Synchrony2025 Roundtable on neuroenergetics in autism. Excess NO → oxidative stress → mitochondrial strain. Our nNOS-targeted small molecule aims to restore balance. #NO #Autism linkedin.com/posts/the-brai…

🔙 #ThrowbackThursday: 2023 Adv Sci paper “The NO answer for ASD” showed that nitric‑oxide modulation can reverse autism‑like behavior 👉 advanced.onlinelibrary.wiley.com/doi/full/10.10… @NeuroNOS is turning that insight into a first‑in‑human nNOS small‑molecule trial in 2026. #NO #Autism #ASD

We're honored to be highlighted by @brainfdn for our work on nitric oxide modulation in #autism. Proud to share the science — and the stage — at #Synchrony2025. linkedin.com/feed/update/ur… #NeuroNOS #NitricOxide #TranslationalResearch #ASD #CNS #DrugDevelopment

🎧 Prof. @haitham_amal, CSO @NeuroNOS, explains how NO dysregulation drives Phelan‑McDermid Syndrome (PMS) & how our FDA‑orphan small molecule advances to first‑in‑human trials in 2026. Watch ▶️ youtube.com/watch?v=YdKiIA… #PMSF #CureSHANK #RareDisease #Autism #DrugDiscovery

@Neuro_NOS is excited to share the BIG news from the #FDA! The #FDA granted us an Orphan Drug Designation for #PhelanMcDermidSyndrome, a Neurodevelopmental Disorder Linked to #Autism #OrphanDrug #NitricOxide #PMS #RareDisease nasdaq.com/press-release/…